Orphan Drugs Market 2020 Global Industry Trends, Size, Share Analysis Report. According to this report Global Orphan Drugs Market will rise from Covid-19 crisis at moderate growth rate during 2020 to 2026. Orphan Drugs Market includes comprehensive information derived from depth study on Orphan Drugs Industry historical and forecast market data. Global Orphan Drugs Market Size To Expand moderately as the new developments in Orphan Drugs and Impact of COVID19 over the forecast period 2020 to 2026.
Orphan Drugs Market report provides depth analysis of the market impact and new opportunities created by the COVID19/CORONA Virus pandemic. Report covers Orphan Drugs Market report is helpful for strategists, marketers and senior management, And Key Players in Orphan Drugs Industry.
Global Orphan Drugs Market Insights:
Report Analyzes Global Orphan Drugs Market Growth Size, Share And Trends by Therapy Area (Oncology, Blood, CNS, Endocrine, Cardiovascular, Respiratory, Immunomodulatory), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales) and Regional Forecast, 2018 – 2025.
Some of the companies operating the industry are:
- Bayer AG
- Hoffmann-La Roche Ltd.
- Alexion Pharmaceuticals Inc.
- Novo Nordisk A/S
- Novartis AG
- Bristol-Myers Squibb Company
- AstraZeneca plc.
- Daiichi Sankyo Company Limited
- GlaxoSmithKline plc.
- Amgen Inc
The oncology segment is witnessing considerably high demand on account of the rising number of patients suffering from different types of cancers. This also increases the demand for novel therapeutics, which as per the report will bode well for the global orphan drugs market. According to the National Center for Health Statistics, the U.S. is likely to witness around 1,762,450 new cancer cases in 2019. Spurred by these numbers, the demand for orphan drugs is likely to increase in the coming years. Governments are investing heavily to build a strong framework for supporting drug development, thus offering a significant impetus to the orphan drugs market. Furthermore, the return on investment, with regards to orphan drugs, is expected to be higher than non-orphan drugs, which in turn is increasing the demand for orphan drug therapeutics worldwide.
Recent impetus to drug development is expected to be the primary factor responsible for the emergence of new players. These new players are likely to focus their work on developing elementary drugs and later produce advanced or complex orphan drugs. Some of the leading players in the market are Amgen Inc., Biogen, Actelion Pharmaceuticals Ltd., and Bayer AG. Of these, Amgen received a recent approval from the Scottish Medicines Consortium (SMC). The approval was for the routine use of orphan drug called Blincyto developed for Parkinson disease. The expertise and experience of these companies is expected to elevate the manufacturing of orphan drugs by 2025.
Regional Market Overview:
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Regional analysis is another highly comprehensive part of the research and analysis study of the global market presented in the report. This section sheds light on the sales growth of different regional and country-level markets. For the historical and forecast period to 2024, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market.
Governments in North America are increasingly spending on the research and development (R&D) of orphan drugs and technologies. This is further helping the orphan drugs market to grow impressively in this region. Asia Pacific, on the other hand, is anticipated to show a higher rate of growth on account of rising prevalence of rare diseases such as chronic lymphocytic leukemia. Also, the region is expected to offer lucrative growth opportunities as a result of the rapid expansion of healthcare infrastructure.
- Orphan Drugs Key Players
- Orphan Drugs Suppliers
- Research and Development (RandD) Companies
- Distributer and Supplier companies
- End Users
- Consultants and Investment bankers
- Government as well as Independent Regulatory Authorities
The Orphan Drugs Market report examines competitive scenario by analyzing key players in the market. The company profiling of leading market players is included this report with Porter’s five forces analysis and Value Chain analysis. Further, the strategies exercised by the companies for expansion of business through mergers, acquisitions, and other business development measures are discussed in the report. The financial parameters which are assessed include the sales, profits and the overall revenue generated by the key players of Market.
In-depth information about the latest Orphan Drugs Industry trends, opportunities, and challenges.
Extensive analysis of the growth drivers And barriers.
Competitive landscape consisting of investments, agreements, contracts, novel product launches, strategic collaborations, and mergers and acquisitions.
List of the segments and the niche areas.
Comprehensive details about the strategies that are being adopted by key players.
Table of Content:
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
- Executive Summary
- Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
- Key Insights
4.1. Prevalence of Key Indications, 2017 (Key Countries)
4.2. Economic (Key Countries)
4.3. Key Mergers and Acquisitions
4.4. Pricing Analysis, Key Players, 2017
4.5. Overview: New Developments in Orphan Drugs
- Global Orphan Drugs Market Analysis, Insights and Forecast, 2014-2025
5.1. Key Findings / Summary
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune -411045, Maharashtra, India.
US: +1 424 253 0390
UK: +44 2071 939123
APAC: +91 744 740 1245